BACKGROUND: In experimental animal models, long-term in vivo treatment with nitroglycerin (NTG) induces both endothelial dysfunction and tolerance to nitrates. However, it is still controversial whether nitrate tolerance in humans is associated with both endothelial dysfunction and impaired vascular response to nitrovasodilator-derived NO. METHODS AND RESULTS:Patients undergoing elective bypass surgery were randomized to receive 48 hours of continuous NTG infusion (NTG group) or no nitrate therapy (control group). Segments of surgically removed arteria mammaria, vena saphena, and arteria radialis not required for the bypass procedure were used to examine (1) the vascular responsiveness to NTG and the endothelium-dependent vasodilator acetylcholine; (2) the expression of the NO target, the soluble guanylyl cyclase; (3) the expression of the soluble guanylyl cyclase/cGMP effector target, the cGMP-dependent protein kinase (cGK); and (4) the cGK activity as assessed by the phosphorylation state of its vascular substrate, the vasodilator-stimulated phosphoprotein at serine(239) (P-VASP). NTG treatment caused a marked degree of nitrate tolerance in all 3 vessel types studied and a significant cross-tolerance to the endothelium-dependent vasodilator acetylcholine in A. mammaria and A. radialis. Although soluble guanylyl cyclase, cGK-I, and VASP expression levels were not modified by NTG treatment, a marked decrease of P-VASP, a surrogate parameter for in-vivo cGK-I activity, was observed. CONCLUSIONS: We conclude that long-term NTG treatment induces endothelial dysfunction and impaired vascular NO/cGMP signaling in humans, which can be monitored by measuring P-VASP levels.
RCT Entities:
BACKGROUND: In experimental animal models, long-term in vivo treatment with nitroglycerin (NTG) induces both endothelial dysfunction and tolerance to nitrates. However, it is still controversial whether nitrate tolerance in humans is associated with both endothelial dysfunction and impaired vascular response to nitrovasodilator-derived NO. METHODS AND RESULTS:Patients undergoing elective bypass surgery were randomized to receive 48 hours of continuous NTG infusion (NTG group) or no nitrate therapy (control group). Segments of surgically removed arteria mammaria, vena saphena, and arteria radialis not required for the bypass procedure were used to examine (1) the vascular responsiveness to NTG and the endothelium-dependent vasodilator acetylcholine; (2) the expression of the NO target, the soluble guanylyl cyclase; (3) the expression of the soluble guanylyl cyclase/cGMP effector target, the cGMP-dependent protein kinase (cGK); and (4) the cGK activity as assessed by the phosphorylation state of its vascular substrate, the vasodilator-stimulated phosphoprotein at serine(239) (P-VASP). NTG treatment caused a marked degree of nitrate tolerance in all 3 vessel types studied and a significant cross-tolerance to the endothelium-dependent vasodilator acetylcholine in A. mammaria and A. radialis. Although soluble guanylyl cyclase, cGK-I, and VASP expression levels were not modified by NTG treatment, a marked decrease of P-VASP, a surrogate parameter for in-vivo cGK-I activity, was observed. CONCLUSIONS: We conclude that long-term NTG treatment induces endothelial dysfunction and impaired vascular NO/cGMP signaling in humans, which can be monitored by measuring P-VASP levels.
Authors: Jeroen Frijhoff; Paul G Winyard; Neven Zarkovic; Sean S Davies; Roland Stocker; David Cheng; Annie R Knight; Emma Louise Taylor; Jeannette Oettrich; Tatjana Ruskovska; Ana Cipak Gasparovic; Antonio Cuadrado; Daniela Weber; Henrik Enghusen Poulsen; Tilman Grune; Harald H H W Schmidt; Pietro Ghezzi Journal: Antioxid Redox Signal Date: 2015-10-26 Impact factor: 8.401
Authors: P Wenzel; U Hink; M Oelze; A Seeling; T Isse; K Bruns; L Steinhoff; M Brandt; A L Kleschyov; E Schulz; K Lange; H Weiner; J Lehmann; K J Lackner; T Kawamoto; T Münzel; A Daiber Journal: Br J Pharmacol Date: 2007-01-15 Impact factor: 8.739
Authors: S Schuhmacher; E Schulz; M Oelze; A König; C Roegler; K Lange; L Sydow; T Kawamoto; P Wenzel; T Münzel; J Lehmann; A Daiber Journal: Br J Pharmacol Date: 2009-06-25 Impact factor: 8.739
Authors: Brandi M Wynne; Hicham Labazi; Zidonia N Carneiro; Rita C Tostes; R Clinton Webb Journal: Eur J Pharmacol Date: 2017-08-20 Impact factor: 4.432
Authors: Kathryn N Farrow; Beezly S Groh; Paul T Schumacker; Satyan Lakshminrusimha; Lyubov Czech; Sylvia F Gugino; James A Russell; Robin H Steinhorn Journal: Circ Res Date: 2007-11-08 Impact factor: 17.367